On Sept. 29, 2020, AXIM Biotechnologies announced that it had filed a provisional patent for a first-in-class face mask that captures and deactivates SARS-CoV-2, the coronavirus responsible for the ongoing COVID-19 pandemic.

AXIM developed a cost-effective treatment for the face mask surfaces that utilizes a proprietary set of reagents that are permanently embedded into the mask filter which then captures the virus instantaneously on contact.